CA2548512A1 - Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases - Google Patents

Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases Download PDF

Info

Publication number
CA2548512A1
CA2548512A1 CA002548512A CA2548512A CA2548512A1 CA 2548512 A1 CA2548512 A1 CA 2548512A1 CA 002548512 A CA002548512 A CA 002548512A CA 2548512 A CA2548512 A CA 2548512A CA 2548512 A1 CA2548512 A1 CA 2548512A1
Authority
CA
Canada
Prior art keywords
adjuvant
immunogenic composition
composition according
oil
mpl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002548512A
Other languages
English (en)
French (fr)
Inventor
Pascal Mettens
Catherine Uyttenhove
Jacques Van Snick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Ludwig Cancer Research
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2548512A1 publication Critical patent/CA2548512A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002548512A 2003-12-16 2004-12-14 Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases Abandoned CA2548512A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0329146.5A GB0329146D0 (en) 2003-12-16 2003-12-16 Vaccine
GB0329146.5 2003-12-16
PCT/EP2004/014379 WO2005058349A2 (en) 2003-12-16 2004-12-14 Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
CA2548512A1 true CA2548512A1 (en) 2005-06-30

Family

ID=30471161

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002548512A Abandoned CA2548512A1 (en) 2003-12-16 2004-12-14 Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases

Country Status (6)

Country Link
US (1) US20070048261A1 (cg-RX-API-DMAC7.html)
EP (1) EP1694358A2 (cg-RX-API-DMAC7.html)
JP (1) JP2007513992A (cg-RX-API-DMAC7.html)
CA (1) CA2548512A1 (cg-RX-API-DMAC7.html)
GB (1) GB0329146D0 (cg-RX-API-DMAC7.html)
WO (1) WO2005058349A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005108425A1 (en) * 2004-05-10 2005-11-17 Cytos Biotechnology Ag Il-23 p19 antigen array and uses thereof
ES2544877T3 (es) 2005-10-12 2015-09-04 Idera Pharmaceuticals Compuestos oligonucleótidos inmuno reguladores (IRO) para modular la respuesta inmune basada en receptor semejante a Toll
US8377898B2 (en) * 2006-10-12 2013-02-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
EP3087988A3 (en) 2008-10-06 2017-03-01 Idera Pharmaceuticals, Inc. Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto
EP2480251B1 (en) 2009-09-21 2025-12-03 Peptinov Carrier conjugates of il-23-peptides and their induced antibodies
CN107012149A (zh) 2010-11-19 2017-08-04 艾德拉药物股份有限公司 调控基于toll‑样受体的免疫应答的免疫调节寡核苷酸(iro)化合物
AU2014235120B2 (en) * 2013-03-15 2017-01-05 The Trustees Of The University Of Pennsylvania Vaccines having an antigen and interleukin-23 as an adjuvant
CN105705522B (zh) * 2013-05-14 2020-09-15 上海亨臻实业有限公司 针对低免疫原性蛋白的表位疫苗及其制法和用途
WO2015157561A1 (en) * 2014-04-09 2015-10-15 La Jolla Institute For Allergy And Immunology Specific and unique t cell responses and molecular signatures for treatment and diagnosis of mycobacterium tuberculosis
CA2986494A1 (en) * 2015-06-03 2016-12-08 Affiris Ag Il-23-p19 vaccines
GB201522329D0 (en) * 2015-12-17 2016-02-03 Glaxosmithkline Biolog S A And Inst Nat De La Sante Et De La Rech Medicale Inserm And Université Pie Use of adjuvants for the prevention and/or treatment of autoimmune diseases
PL3458083T3 (pl) 2016-05-18 2023-03-13 Modernatx, Inc. Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
WO2019051127A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
GB201907413D0 (en) * 2019-05-24 2019-07-10 Univ Helsinki Viral vector
AU2021311894B2 (en) 2020-07-22 2025-02-27 3H Bio. Co., Ltd. Peptide for immunotherapeutic agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
WO1996040755A1 (en) * 1995-06-07 1996-12-19 Dlo Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) An improved peptide, immunogenic composition and vaccine or medical preparation, a method to immunise animals against the hormone lhrh, and analogs of the lhrh tandem repeat peptide and their use as vaccine
AU1407997A (en) * 1995-12-01 1997-06-19 Beth Israel Hospital Il-12 p40 subunit fusion polypeptides and uses thereof
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
KR100764256B1 (ko) * 1998-01-23 2007-10-05 에프. 호프만-라 로슈 아게 인간 인터루킨-12에 대한 항체
ATE480566T1 (de) * 1998-06-15 2010-09-15 Quest Pharmatech Inc Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US20030082179A1 (en) * 2001-07-03 2003-05-01 Hutchison James Scott Parathyroid hormone antibodies and related methods

Also Published As

Publication number Publication date
GB0329146D0 (en) 2004-01-21
JP2007513992A (ja) 2007-05-31
EP1694358A2 (en) 2006-08-30
WO2005058349A3 (en) 2005-08-25
WO2005058349A2 (en) 2005-06-30
US20070048261A1 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
Kensil et al. QS-21: a water-soluble triterpene glycoside adjuvant
JP4805242B2 (ja) ワクチン
US20070048261A1 (en) Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases
Kensil et al. Current vaccine adjuvants: an overview of a diverse class
US20030095974A1 (en) Oil in water emulsions containing saponins
US20030138434A1 (en) Agents for enhancing the immune response
JP2001515870A (ja) ワクチン
KR20070029730A (ko) 애쥬번트 처리된 시가 독소 ｂ-서브유닛을 기재로 하는 백신
HUP0101619A2 (hu) Adjuvánskészítmények
JP2003502388A5 (cg-RX-API-DMAC7.html)
JP5307859B2 (ja) ワクチン
KR20080018201A (ko) Ｅ．ｃｏｌｉ 열 독소의 ｂ­서브유닛 및 항원 및애주번트를 포함하는 백신 조성물
US20100266672A1 (en) Vaccines
TWI239848B (en) Adjuvant combination formulations
WO2000074716A2 (en) Ige peptides for allergy immunotherapy
JP2009517422A (ja) 非生抗原性ベクターを含むワクチン
Ronco et al. Adjuvants for mucosal vaccines
Siegrist et al. Antigen-presentation systems, immunomodulators, and immune responses to vaccines
AU2002355945A1 (en) Agents for enhancing the immune response
MXPA00009887A (en) Adjuvant compositions
CZ20003732A3 (cs) Pomocný prostředek
MXPA01010654A (en) Vaccines

Legal Events

Date Code Title Description
FZDE Discontinued